Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2020

View Archived Issues

First COVID-19 patients dosed in phase II study of peginterferon lambda-1a

FDA clears IND application for ZN-d5 for hematologic malignancies

Pancreatic cancer uses autophagy to hide from immune system

Mesoblast initiates phase II/III study of remestemcel-L in patients with COVID-19 ARDS

SIAIS-117, novel ALK degrader as potential therapy for ALK-positive cancer types

Discovery of a novel highly potent and orally active EED inhibitor

Novartis presents preclinical data for TNO-155

Terns patents new THR-beta agonists

Thwarting the hijacker: in vitro study gives "blueprint", drug leads for SARS-CoV-2

Tumor burden reduction seen with Pexa-Vec vaccine in phase I renal cell carcinoma trial

Janssen BioPharma presents new antivirals

Sareum Holdings identifies TYK2 inhibitors

Morphic Therapeutic synthesizes integrin alphavbeta6 antagonists

Medshine Discovery divulges new GLS1 inhibitors

Restoring synaptic transmission for rare neurodevelopmental disease

Neutralizing RSV

Loss-of-function variant in CDC25B causes a syndrome including cardiomyopathy and endocrinopathies

Serum amyloid A may be useful as a marker of COVID-19 severity and prognosis

Preclinical and preliminary phase I results presented for menin/MLL interaction inhibitor SNDX-5613

IPN-60090: a GLS1 inhibitor for the oral treatment of KEAP1/NFE2L2-mutant NSCLC and ASNS-low HGSOC

Phase II trial of nomacopan in bullous pemphigoid meets primary and key secondary efficacy endpoints

Newron discontinues development of sarizotan in Rett syndrome following STARS data

RECCE-327 shows significant antibacterial activity against N. gonorrhoeae bacteria in mice

FDA approves Darzalex Faspro for multiple myeloma

Phase IIb study of STA-363 for disc-related low back pain cleared to begin in Spain

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...